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Abstract: Susceptibility to prostate or endometrial cancer is linked with obesity, a state of 
oestrogen  excess.  Oestrogen  receptor  (ER)  splice  variants  may  be  responsible  for  the 
tissue-level  of  ER  activity.  Such  micro-environmental  regulation  may  modulate  cancer 
initiation and/or progression mechanisms. Real-time reverse transcriptase (RT) polymerase 
chain reaction (PCR) was used to quantitatively assess the levels of four ER splice variants 
(ER3, ER5, ER2 and ER5), plus the full-length parent isoforms ER and ER1, in 
high-risk [tumour-adjacent prostate (n = 10) or endometrial cancer (n = 9)] vs. low-risk 
[benign prostate (n = 12) or endometrium (n = 9)], as well as a comparison of UK (n = 12) 
vs. Indian (n = 15) benign prostate. All three tissue groups expressed the ER splice variants 
at similar levels, apart from ER5. This splice variant was markedly raised in all of the 
tumour-adjacent  prostate  samples  compared  to  benign  tissues.  Immunofluorescence 
analysis for ER2 in prostate tissue demonstrated that such splice variants are present in 
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comparable, if not greater, amounts as the parent full-length isoform. This small pilot study 
demonstrates the ubiquitous nature of ER splice variants in these tissue sites and suggests 
that ER5 may be involved in progression of prostate adenocarcinoma. 
Keywords: endometrial cancer; oestrogen receptor; prostate cancer; real-time RT PCR; 
splice variant 
 
Abbreviations 
C: calibrator control; 
CaP: prostate cancer; 
CT: threshold cycle; 
ER: oestrogen receptor; 
GSPBS: 5% normal goat serum in PBS; 
PI: propidium iodide; 
PMT: photomultiplier tubes; 
PROS: benign prostate tissues; 
PSA: prostate-specific antigen; 
RRP: radical retro-pubic prostatectomy; 
RT-PCR: real time polymerase chain reaction; 
TA: tumour-adjacent; 
TURP: trans-urethral resection of the prostate. 
1. Introduction 
Prostate  and  endometrial  cancers  are  the  most  common  cancers  of  the  reproductive  tract  in  
UK-resident men and women, respectively. Indeed, prostate cancer (CaP) is the most common cancer 
overall and the second most common cause of cancer death in men (Office for National Statistics  
2007 data). Both exhibit a marked geographical variation in incidence, with endometrial cancer and 
clinically-significant CaP being far more common in affluent countries, such as the USA and Western 
Europe [1]. Even within individual nations, variation exists between urban and rural populations [2,3]. 
Both cancers have been linked with a high saturated fat intake in addition to other dietary and/or 
environmental factors but obesity plays a major role [4,5]. 
Tissues  of  the  reproductive  organs  are  highly  influenced  by  oestrogens.  The  endometrium 
proliferates in response to oestrogenic stimulation; when unopposed by progesterone, this commonly 
results in hyperplasia and occasionally, in endometrioid endometrial cancer [6]. It has recently been 
suggested that oestrogen also plays a role in prostatic carcinogenesis [7], possibly via TMPRSS2:ERG 
fusion transcripts [8]. The CYP19-encoded aromatase, responsible for the peripheral conversion of 
adrenal  and  testicular  androgens  to  oestrogens,  is  highly  expressed  in  adipose  tissue.  This  is  the 
primary source of circulating oestrogen in men and postmenopausal women [9]. The UK and India 
have clear differences in diet and average body mass index. Therefore differing oestrogen status may Int. J. Environ. Res. Public Health 2010, 7                 
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contribute  to  the  marked  dissimilarity  in  the  prevalence  of  CaP  between  these  populations. 
Reproductive  differences  between richer and  poorer  countries,  especially in  contraceptive  use and 
childbearing, are also important contributors to the incidence of endometrial cancer. 
Tissues of the reproductive organs display complex regulation of sex steroid secretion. Feedback 
loops exist with the pituitary and hypothalamus to control circulating gonadal hormone levels. These 
have less influence on peripherally-generated oestrogens. Oestrogen is a powerful promoter of cell 
division and so it is plausible that a further level of regulation occurs in sensitive tissues at the cellular 
level. There is compelling circumstantial evidence to suggest that this occurs, at least in part, via 
oestrogen receptor (ER) splice variants [10]. ERs exist as two separately encoded isoforms, ER alpha 
(ER) and ER beta (ER1). Alternative processing of precursor mRNA results in a range of splice 
variant forms, several of which are translated into proteins. Most ER splice variants involve exon 
deletions; ER3 lacks a DNA binding domain but is otherwise intact and ER5 is truncated, missing 
the  entire  ligand  binding  domain.  Both  influence  the  activity  of  full-length  ER.  ER3  inhibits  
ER-mediated transcription but also activates the vascular endothelial growth factor promoter [11]. 
ER5  binds  DNA  (with  weak  constitutive  activity)  and  competitively  inhibits  the  binding  of  
ER [12]. ER2 and ER5 both have an alternative exon 8. This alters their ability to bind ligand and 
recruit cofactors [13]. Both are widely expressed, often at similar levels to the full-length ER1 [14]. 
ER2 does not bind ligand or directly stimulate transcription. ER2 and ER5 are able to form dimers 
with ER and ER1. ER5 preferentially binds ER, inhibiting its effect [13,15]. 
The four splice variants selected for this study (ER3, ER5, ER2 and ER5) have all been 
previously found in uterine tissue [16-18]. No ER splice variants have previously been described in 
the prostate but both ER2 and ER5 are known to be present [19]. This small pilot study aimed to 
discover whether the level of expression of these ER splice variants is linked to the risk of malignant 
transformation. In order to do this we studied three pairs of hormone-sensitive tissues: firstly, normal 
endometrium vs. tumour-adjacent (TA) tissue; secondly, benign prostate vs. TA tissue; and, thirdly, 
benign prostate tissues from high-risk (UK) vs. low-risk (Indian) populations. Our objective was to 
determine  whether  a  putative  role  for  ER  splice  variants  in  the  pathogenesis  of  prostate  and 
endometrial cancers could be identified; this would then need to be verified in a larger cohort study. 
2. Materials and Methods 
2.1. Study Participants 
This  study  was  conducted  with  appropriate  ethical  approval  at  two  centres;  for  UK-resident 
participants  under  LREC  nos.  06/Q1309/76  and  05/Q1302/83  (Preston,  Chorley and  South  Ribble 
Ethical Committee), whilst for India-resident participants institutional ethical approval in Workhardt 
hospital (Kolkata, India) was obtained. 
For  benign prostate  tissues  (PROS),  patients  undergoing trans-urethral resection  of the prostate 
(TURP) were identified and prospectively consented based on their having a low risk of harbouring 
CaP  (no  previous  history  of  CaP,  benign-feeling  gland  on  digital  rectal  examination  and  
prostate-specific antigen (PSA) < 10 ng/mL serum); except for one patient, PROS 9, who had an open 
prostatectomy for a >200 g-sized prostate (PSA = 34 ng/mL, final histology benign). For TA prostate Int. J. Environ. Res. Public Health 2010, 7                 
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tissues, appropriate patients undergoing retro-pubic radical prostatectomy (RRP) for biopsy-identified 
localized CaP were identified and prospectively consented. Among those undergoing RPP for localized 
CaP, study participants were chosen with low volume of the disease on prostate biopsies and low PSA 
(<15  ng/mL).  All  PROS  and  TA prostate  tissues  were  collected in  Preston  (UK)  from  Caucasian 
British, UK-resident men. The Indian prostate specimens (IND) were collected in Kolkata (India) from 
India-resident, Indian men undergoing TURP. 
For  endometrial  tissues,  appropriate  women  were  identified  and  prospectively  consented.  TA 
endometrial tissues were obtained from patients with biopsy-proven endometrial cancer undergoing 
hysterectomy as part of their initial treatment. In order to minimise variation only tissues from women 
with  grade  2  endometrioid  endometrial  carcinoma  were  used  in  this  study.  Control  tissues  were 
obtained  from  patients  undergoing  hysterectomy  for  benign  conditions.  All  were  pre-menopausal 
women in the proliferative phase of a natural menstrual cycle. 
2.2. Tissue Collection and Storage 
Following surgical resection, prostate chips were immersed in a cold 0.9% saline solution; other 
tissues  were  placed  in  a  dry,  clean  plastic  pot.  All  specimens  were  transported  directly  to  the 
laboratory. Tissues were dissected by a consultant histopathologist under standard clean conditions. 
For endometrial tissue, the cavity was exposed by first amputating the cervix and, then opening the 
anterior wall of the uterus. In benign cases, a small sample of representative endometrium (5 mm  5 mm) 
was  shaved  off  the  underlying  myometrium.  In  malignant  cases,  the  tumour  was  macroscopically 
identified and a piece of normal-looking endometrium sampled as above, on the opposite side of the 
uterus from the tumour site (precise distances dependent on size of uterus, usually 2–3 cm from tumour 
edge). For prostate TA tissue, macroscopically-normal material assumed to be CaP-free was selected. 
This comprised material from the lobe that showed no or minimal CaP on pre-operative biopsy. A 
piece of tissue measuring approximately 1.5 cm  0.3 cm was incised from the most peripheral and 
posterolateral aspect of the gland. Gross tumour is easily identified in macroscopic uterine and prostate 
specimens, although using this method it is not possible to exclude small areas of premalignant disease 
or early carcinoma. Benign prostate tissue obtained from TURP did not require dissection. Specimens 
were placed in RNAlater solution (QIAGEN Ltd., UK), kept at 4 ° C for 24 h and then transferred for 
storage at −85 ° C for gene expression analysis. Time between surgical resection and placement in 
RNAlater or formalin was <15 min. The tissues from India were transported to the UK with adequate 
precautions taken to maintain the appropriate temperature throughout the journey. 
2.3. Quantitative Real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
The  method  of  RNA  extraction,  reverse  transcription  and  real-time  RT-PCR  for  prostate  and 
endometrial tissues has been described previously [20,21]. Briefly, tissue was ground under liquid 
nitrogen. Total RNA extraction was performed using the Qiagen RNeasy® Kit in combination with the 
Qiagen  RNase-free  DNase  kit  (QIAGEN  Ltd.).  RNA  (0.4  g)  was  reverse  transcribed  in  a  final 
volume  of  20  L  containing  Taqman®  reverse  transcription  reagents  (Applied  Biosystems,  UK):  
1  Taqman RT buffer; MgCl2 (5.5 mM); oligo d(T)16 (2.5 M); dNTP mix (dGTP, dCTP, dATP and 
dTTP;  each  at  a  concentration  of  500  M);  RNase  inhibitor  (0.4  U/L);  reverse  transcriptase Int. J. Environ. Res. Public Health 2010, 7                 
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(MultiScribe™) (1.25 U/L) and RNase-free water. Reaction mixtures were then incubated at 25 ° C 
(10 min), 48 ° C (30 min) and 95 ° C (5 min). cDNA samples were stored at −20 ° C prior to use. 
Primers (Table 1) for ER, ER and the endogenous control -ACTIN were chosen using Primer 
Express  software  2.0  (Applied  Biosystems)  and  designed  so  that  one  primer  spanned  an  exon 
boundary. Specificity was confirmed using the NCBI BLAST search tool. The splice variant primers 
ER3, ER5, ER2 and ER5 were designed and specificity confirmed using the Primer-BLAST 
tool on the NCBI website. One of the pair was designed across the splice boundary, with at least six 
bases overlapping, to ensure maximum specificity. All primers (Table 1) were validated. Quantitative  
real-time  PCR  was  performed  using  the  ABI  Prism  7000  Sequence  Detection  System  (Applied 
Biosystems). Reaction mixtures contained 1  SYBR® Green PCR master mix (Applied Biosystems); 
forward and reverse primers (Invitrogen, Paisley, UK) at a concentration of 300 nM; a 20 ng cDNA 
template; made to a total volume of 25 L with sterile H2O. Thermal cycling parameters included 
activation  at  95  ° C  (10  min)  followed  by  60  cycles  each  of  denaturation  at  95  ° C  (15  sec)  and 
annealing/extending at 60 °C (1 min). Each reaction was performed in triplicate and ―no-template‖ 
controls were included in each experiment. Dissociation curves were run to eliminate non-specific 
amplification, including primer-dimers. 
Table 1. Primer sequences used for RT-PCR. 
Gene Symbol  Primer  Sequence (5‘–3‘) 
ER  ER-F 
ER-R 
TGG ACA GGA ACC AGG GAA AAT 
GAG ATG ATG TAG CCA GCA GCA T 
ER3  ER3-F 
ER3-R 
AGA AGT ATT CAA GGG ATA CGA AAA G 
ATC ATC TCT CTG GCG CTT GT 
ER5  ER5-F 
ER5-R 
AGG GTG CCA GGA ACC A 
GAT GTA GCC AGC AGC ATG TC 
ER1  ER-F 
ER-R 
TGT AAA CAG AGA GAC ACT GAA AAG GAA 
CCT CTT TGA ACC TGG ACC AGT AA 
ER2  ER2-F 
ER2-R 
GCA TGC GAG GGC AGA A 
TTC TTT AGG CCA CCG AGT TG 
ER5  ER5-F 
ER5-R 
CAC GGA GGG TGA AGT GAT TT 
ATT CCA AAT GAG GCA TTC ATT 
-ACTIN  -ACTIN-F 
-ACTIN-R 
CCT GGC ACC CAG CAC AAT 
GCC GAT CCA CAC GGA GTA CT 
F, forward primer; R, reverse primer. 
2.4. Immunofluorescence 
Tissues  were  fixed  in  formalin  prior  to  wax-embedding  and  subsequent  immunofluorescence 
staining  of  tissue  sections  (4-m  thick)  was  performed  manually.  Staining  took  place  following  
de-waxing and re-hydration. High-temperature antigen retrieval was performed by heating the tissue 
sections in citrate buffer (pH 6) or glycine/EDTA (pH 8) for 3 min, under full pressure in an electric 
pressure cooker. Sections were then permeabilised using 0.1% Triton X-100 for 20 min, after which 
they  were  rinsed  in  PBS  buffer  (pH  7.4).  Endogenous  avidin/biotin  was  blocked  using  a 
streptavidin/biotin blocking kit (Vector Labs, UK), then washed in PBS twice for 2 min, followed by Int. J. Environ. Res. Public Health 2010, 7                 
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incubation in 5% normal goat serum in PBS (GSPBS) for 20 min. Anti-ER (ab288) and anti-ER2 
(MCA2279ST)  antibodies  were  purchased  from  Abcam  and  AbD  serotec,  respectively.  Antisera 
dilutions were 1:50 (anti-ER) and 1:50 (anti-ER2) in GSPBS. Tissue sections were incubated with 
primary antisera overnight at 4 ° C in a moist chamber. For each immunolabelling, negative controls in 
which the primary antibody step was replaced by non-specific antibody were run. Tissue sections were 
washed three times in PBS for 5 min, followed by three 5-min washes in distilled H2O. Slides were 
incubated with secondary biotin-conjugated goat anti-mouse IgG antisera (1:200; Vector Labs, UK) in 
GSPBS for 30 min, followed by two washes in PBS for 5 min. Tissue sections were then incubated in 
tertiary streptavidin fluorescein (1:100; Vector Labs) in PBS for 15 min, after which they were washed 
twice for 5 min each with PBS. After the final wash, coverslips were mounted using vector shield 
(Vector Labs) containing propidium iodide (PI). Immunofluorescence images were acquired using a 
Leica  TCS  SP2  confocal  system  (Leica  Microsystems,  Germany),  equipped  with  a  DMIRE2 
microscope,  40 objective lens (NA 1.25) and 488 nm argon laser line. Detection was acquired via 
two  internal  photomultiplier  tubes  (PMT)  over  the  range  500–540  nm  for  fluorescein  (green—to 
localise antibody-labelled protein) and 624–707 nm for PI (red—to stain nuclei). Control sections were 
used to identify tissue auto-fluorescence and non-specific staining. Subtraction was carried out by 
decreasing fluorescein PMT voltage until all auto-fluorescence, either non-specific- and/or majority of  
lipofuscin-derived, was removed from the negative control images. These parameters were saved to the 
system and applied to all the subsequent test slides to identify and localise specific antibody staining. 
Images were processed using Leica confocal software (version 2.61). 
3. Results 
3.1. Proliferative Endometrium vs. Grade 2 Endometrioid TA Tissue 
The  range  of  averaged  threshold  cycle  (CT)  values  of  amplified  cDNA  for  ER  in  benign 
endometrium were 23.9–29.0 and, in TA tissue 23.0–27.2. For ER3, the range was 28.6–32.5 in 
benign endometrium and 28.3–32.2 in TA tissue. For ER5, the range was 30.2–33.7 for benign 
endometrium and 30.0–33.3 for TA tissue. For ER1, the range was 20.7–36.1 for benign endometrium 
and  24.7–37.2  for  TA  tissue.  For  ER2,  the  range  was  32.3–34.5  for  benign  endometrium  and  
30.9–33.4 for TA tissue. Finally, the range for  ER5 was 35.1–58.7 for benign endometrium and  
33.9–38.9 for TA tissue. Therefore, all of the tissue samples examined expressed full-length ER and 
ER1 together with all four splice variants. Overall, transcripts for ER and its splice variants were 
present at higher levels than ER and its splice variants (see Supplementary Information, Table 1S). 
There was a trend towards greater relative expression of ER5 in TA tissue compared with benign 
endometrium (Table 2). This was not conclusive, however, and the origin of the tissue did not appear 
to influence the levels of the other splice variants or full-length ERs. Int. J. Environ. Res. Public Health 2010, 7                 
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Table 2. Benign proliferative endometrium (N) vs. grade 2 endometrioid tumour-adjacent 
(TA) endometrial tissue: relative gene expression (min-max expression levels). 
Patient 
code 
 
ER 
 
ER3 
 
ER5 
 
ER1 
 
ER2 
 
ER5 
N 1  1 (c)*  
(0.69–1.46) 
1 (c)  
(0.71–1.41) 
1 (c)  
(0.71–1.42) 
1 (c) 
(0.71–1.41) 
1 (c) 
(0.64–1.57) 
1 (c) 
(0.50–2.02) 
N 2  1.06  
(0.92–1.23) 
1.54  
(1.32–1.81) 
0.83  
(0.72–0.96) 
1.95  
(1.28–2.96) 
1.53  
(0.95–2.46) 
3.41  
(2.58–4.51) 
N 3  2.29  
(1.68–3.13) 
4.31  
(3.11–5.97) 
2.24  
(1.71–2.93) 
0.90  
(0.52–1.58) 
1.08  
(0.65–1.81) 
1.15  
(0.62–2.16) 
TA 1   1.07  
(0.77–1.49) 
1.02  
(0.78–1.33) 
0.55  
(0.40–0.75) 
7.36  
(4.75–11.41) 
1.47  
(0.99–2.19) 
8.90  
(6.53–12.13) 
TA 2  1.43  
(1.29–1.58) 
1.77  
(1.54–2.02) 
0.73  
(0.65–0.83) 
1.44  
(1.01–2.05) 
2.82  
(1.88–4.24) 
2.64  
(1.61–4.33) 
TA 3  1.12  
(0.88–1.43) 
1.03  
(0.82–1.29) 
0.74  
(0.52–1.04) 
0.98  
(0.79–1.22) 
1.77  
(1.34–2.33) 
1.00  
(0.59–1.69) 
N 4  1 (c)  
(0.91–1.10) 
1 (c)  
(0.88–1.14) 
1 (c)  
(0.88–1.14) 
1 (c)  
(0.96–1.05) 
1 (c)  
(0.70–1.43) 
1 (c)  
(0.74–1.34) 
N 5  0.61  
(0.49–0.76) 
1.42  
(1.08–1.87) 
0.85  
(0.59–1.23) 
2.32  
(2.10–2.57) 
1.82  
(1.32–2.49) 
2.06  
(0.43–9.80) 
N 6  0.93  
(0.72–1.20) 
0.87  
(0.53–1.42) 
1.14  
(0.85–1.54) 
0.05  
(0.03–0.06) 
0.62  
(0.31–1.27) 
2.56  
(1.36–4.82) 
TA 4  2.13  
(1.91–2.38) 
1.77  
(1.62–1.94) 
2.49  
(2.19–2.82) 
0.02  
(0.01–0.03) 
0.70  
(0.38–1.31) 
16.19  
(10.38–25.23) 
TA 5  2.88  
(2.56–3.25) 
2.13  
(1.89–2.40) 
2.24  
(1.88–2.65) 
0.01  
(0.01–0.02) 
0.57  
(0.43–0.76) 
2.92  
(1.28–4.28) 
TA 6  2.16  
(1.88–2.48) 
1.73  
(1.49–2.02) 
1.11  
(0.86–1.44) 
0.03  
(0.02–0.05) 
5.70  
(4.08–7.96) 
9.76  
(4.02–23.71) 
N 7  1 (c)  
(0.53–1.88) 
1 (c)  
(0.54–1.87) 
1 (c)  
(0.45–2.22) 
1 (c)  
(0.62–1.61) 
1 (c)  
(0.49–2.06) 
1 (c)  
(0.39–2.59) 
N 8  1.12  
(0.64–1.97) 
0.49  
(0.29–0.85) 
0.80  
(0.39–1.67) 
0.41  
(0.23–0.75) 
2.15  
(1.36–3.41) 
NQ 
N 9  0.66  
(0.48–0.91) 
0.63  
(0.45–0.86) 
0.49  
(0.29–0.83) 
0.26  
(0.16–0.44) 
1.69  
(0.84–3.42) 
0.51  
(0.16–1.63) 
TA 7  1.80  
(1.34–2.40) 
1.15  
(0.78–1.69) 
0.78  
(0.59–1.03) 
2.37  
(1.79–3.13) 
2.42  
(1.88–3.12) 
1.77  
(1.01–3.08) 
TA 8  0.98  
(0.68–1.40) 
0.42  
(0.32–0.56) 
0.51  
(0.37–0.71) 
0.87  
(0.62–1.22) 
0.91  
(0.55–1.51) 
0.76  
(0.50–1.17) 
TA 9  1.37  
(0.99–1.89) 
1.05  
(0.81–1.34) 
0.79  
(0.62–1.00) 
0.68  
(0.41–1.13) 
1.59  
(0.76–3.32) 
0.15  
(0.003–7.94) 
NQ, not quantified, detected but only at a very low level; c, calibrator control. 
Patients  who  donated  tissue  for  the  research  purpose  of  this  study  were  chronologically  numbered.  For  inter-
individual variations, the mRNA transcript levels derived from the first patient number was arbitrarily taken as the 
calibrator  control  (*)  and  set  to  1  (for  raw  data,  see  Supplementary  Information,  Table  1S).  Quantitative  gene 
expression was carried out exactly as previously described [20,21], with minimum–maximum expression in brackets. 
Within each experiment, reactions were performed in triplicate and ‗no-template‘ controls were included. Averaged 
threshold cycle (CT) values for each reaction were normalized to -ACTIN values thus giving CT values. Alterations 
in gene expression were determined by comparison with the tissue value assigned as the calibrator, giving CT 
values. Finally, relative gene expression was calculated using the formula 2
-C
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3.2. Benign Prostate vs. Tumour-adjacent Prostate 
The range of averaged CT values of amplified cDNA for ER in benign prostate were 31.6–41.3 and 
in TA tissue 28.8–37.7. For ER3, the range was 32.9–48.2 in benign prostate and 33.5–40.1 in TA 
tissue. For ER5, the range was 39.1–56.1 for benign prostate and 34.2–48.1 for TA tissue. For ER1, 
the range was 31.2–37.2 for benign prostate and 32.6–36.5 for TA tissue. For ER2, the range was 
31.7–37.2 for benign prostate and 23.3–33.5 for TA tissue. Finally, the range for ER5 was 37.5–57.1 
for benign prostate and 36.4–8.2 for TA tissue (see Supplementary Information, Table 2S). Expression 
of full-length ER and ER1 were detected in all benign and TA prostate tissues. All four splice 
variants were detected, although ER5 was expressed at low levels and not demonstrable in several 
samples (PROS 1, PROS 2 and PROS 7; Table 3). 
ER5  expression  was  detected  at  higher  levels  in  TA  tissue  than  benign  tissue,  with  raised 
expression in 2 of 9 benign tissues and 9 of 9 TA tissues. The difference between the highest and the 
lowest expression levels was large. For  ER5 in TA tissue, the range was 9.5–24,154.4 and for 
normal tissue, the range was 0.6–51.4; such a marked difference in the expression profile of this ER 
splice variant indicates a significant underlying role in maintaining the adjacent cancer and would 
justify  further  investigation  (Figure  1).  Additionally,  these  tissues  were  validated  by  a  single 
Pathologist with >25 y experience; although one could not absolutely guarantee that they were free of 
focal CaP, one would expect that the vast majority would be. In light of this observation, these results 
suggest a significant role for ER5 in prostate TA tissue. It is interesting that two of the benign 
tissues exhibited higher levels  of this  mRNA  transcript;  this  could be  due  to  either  ER5  being 
diagnostic of future disease or unidentified CaP. One TA tissue (TA 16) had very high levels of 
expression of ER (300.3) and both of its splice variants (ER3-250.2, ER5-24,154.4). This tissue 
came  from  a  65-y-old  man  with  a  PSA  level  of  6.5  and  a  low  Gleason  grade  of  3  +  3  
(see Supplementary Information, Tables 4S, 5S). After excluding this tissue, the mean expression level 
of ER5 in TA tissue was 63.3, as opposed to 10.3 in benign prostate. Finally, the expression levels 
of both the ERs and the four splice variants studied varies greatly between tissue samples. This was 
particularly notable for ER1 and ER2 in addition to ER5 (described above). Some prostate tissues 
(e.g.,  PROS  8,  PROS  2,  TA  19)  had  high  relative  expression  of  both  ERs  and  several  splice  
variants (Table 3). Int. J. Environ. Res. Public Health 2010, 7                 
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Table 3. Benign prostate tissue (PROS) vs. tumour-adjacent (TA) prostate tissue relative gene expression (min-max expression levels). 
Patient 
code 
 
ER 
 
ER3 
 
ER5 
 
ER1 
 
ER2 
 
ER5 
PROS 1   1 (c)* (0.71–1.41)  1 (c) (0.25–4.10)  1 (c) (0.06–16.2)  5.95 (5.65–6.27)  0.51 (0.36–0.71)  ND 
PROS 2  8.04 (5.59–11.56)  15.6 (8.64–28.17)  1.41 (0.95–2.10)  57.95 (47.1–71.4)  5.04 (3.62–7.03)  ND 
PROS 3  0.70 (0.52–0.93)  0.08 (0.02–0.29)  0.56 (0.06–5.63)  1 (c) (0.58–1.72)  1 (c) (0.87–1.15)  1 (c) (0.78–1.29) 
TA 13   8.13 (3.15–21.0)  1.07 (0.60–1.91)  12.38 (2.75–55.78)  0.65 (0.54–0.78)  0.74 (0.29–1.9)  0.28 (0.23–0.33) 
TA 14  6.59 (3.37–12.88)  1.13 (0.60–2.13)  28.44 (13.79–58.66)  0.54 (0.12–2.49)  1.18 (0.22–6.52)  0.59 (0.11–3.08) 
TA 15  10.9 (7.15–16.6)  2.57 (1.61–4.10)  15.4 (8.40–27.27)  1.81 (0.86–3.82)  1.44 (0.77–2.69)  0.78 (0.23–2.61) 
PROS 4  1 (c) (0.24–4.25)  1 (c) (0.31–3.22)  1 (c) (0.11–9.14)  Insuff  Insuff  Insuff 
PROS 5  0.44 (0.08–2.43)  0.002 (0.001–0.007)  0.63 (0.06–6.76)  Insuff  Insuff  Insuff 
PROS 6  11.39 (3.58–36.29)  11.69 (3.72–36.73)  51.4 (6.78–389.6)  Insuff  Insuff  Insuff 
TA 16  300.3 (202.4–445.4)  250.2 (180.3–347.1)  24,154.4 (10,085.4–57,849.9)  Insuff  Insuff  Insuff 
TA 17   1.26 (0.86–1.86)  0.61 (0.3–1.27)  385.79 (88.89–1,674.4)  Insuff  Insuff  Insuff 
TA 18   1.35 (0.46–3.96)  0.81 (0.3–2.21)  28.4 (11.9–68)  Insuff  Insuff  Insuff 
PROS 7  1 (c) (0.65–1.54)  1 (c) (0.56–1.8)  1 (c) (0.17–5.91)  4.94 (3.49–6.98)  18.24 (15.1–22.12)  ND 
PROS 8  17.39 (13.87–21.8)  37.01 (30.5–44.93)  35.34 (24.23–51.56)  227.5 (207.9–249.0)  95.56 (69.65–131.1)  1.35 (0.31–5.93) 
PROS 9  0.48 (0.26–0.89)  0.29 (0.12–0.68)  0.7 (0.05–9.21)  1 (c) (0.79–1.27)  1 (c) (0.54–1.86)  1 (c) (0.64–1.55) 
TA 19   6.76 (2.83–16.14)  6.53 (2.79–15.3)  15.31 (2.02–116.23)  10.13 (7.19–14.26)  77.62 (28.89–208.6)  0.02 (0.003–0.21) 
TA 20  2.1 (1.83–2.42)  2.07 (1.5–2.86)  10.85 (5.53–21.29)  6.04 (3.58–10.18)  13.01 (6.59–25.68)  1.28 (0.31–5.23) 
TA 21  1.67 (1.5–1.86)  1.29 (0.81–2.06)  9.47 (5.43–16.53)  Insuff  Insuff  Insuff 
TA 22  Insuff  Insuff  Insuff  1.07 (0.81–1.41)  6.58 (5.18–8.36)  1.41 (0.68–2.93) 
ND, not detected; c, calibrator control; Insuff, insufficient material. 
Patients who donated tissue for the research purpose of this study were chronologically numbered. For inter–individual variations, the mRNA transcript levels derived from the first 
patient number was arbitrarily taken as the calibrator control (*) and set to 1 (for raw data, see Supplementary Information, Table 2S). Quantitative gene expression was carried out 
exactly as previously described [20,21], with minimum–maximum expression in brackets. Within each experiment, reactions were performed in triplicate and ‗no-template‘ controls 
were included. Averaged threshold cycle (CT) values for each reaction were normalized to -ACTIN values thus giving CT values. Alterations in gene expression were determined by 
comparison with the tissue value assigned as the calibrator, giving CT values. Finally, relative gene expression was calculated using the formula 2
–C
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Figure  1.  Graphical  representation  of  relative  ERαΔ5  expression  (bars)  with  min-max 
levels  (lines)  in normal  (PROS) vs.  tumour-adjacent  (TA) prostate  tissue.  The  y-axis  is 
split-scale to allow all data to be plotted together. 
 
3.3. UK vs. India Benign Prostate 
The range of averaged CT values of amplified cDNA for ER in UK prostate were 30.2–39.2 and in 
Indian prostate were 33.7–36.8. For ER3, the range was 32.8–40.2 in UK prostate and 35.9–39.1 in 
Indian  prostate.  For  ER5,  the  range  was  38.0–45.4  for  UK  prostate  and  38.3–42.4  for  Indian 
prostate. For ER1, the range was 30.8–39.8 for UK prostate and 32.1–ND for Indian prostate. For 
ER2, the range was 33.2–50.0 for UK prostate and 33.4–53.9 for Indian prostate. Finally, the range 
for  ER5  was  36.7–51.4  for  UK  prostate  and  37.0–55.1  for  Indian  prostate  (see  Supplementary 
Information, Table 3S). 
All tissues described here were benign and obtained from TURP. ER and ER1 were expressed in 
all tissues bar one, IND 5, which lacked ER1. ER2 and ER5 were expressed in all samples tested, as 
was  ER3,  but  ER5  was  not  detected  in  the  sample  IND  2.  Overall  there  was  no  detectable 
difference between the UK and the Indian prostate tissue in expression levels of either the full length 
ER or ER1 or any of the splice variants (Table 4). Int. J. Environ. Res. Public Health 2010, 7                 
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Table 4. Benign UK prostate tissue (PROS) vs. benign Indian prostate tissue (IND) (min–max expression levels). 
Patient 
code 
 
ER 
 
ER3 
 
ER5 
 
ER1 
 
ER2 
 
ER5 
PROS 10  1 (c)* (0.2–4.93)  1 (c) (0.15–6.88)  1 (c) (0.57–1.74)  1 (c) (0.74–1.36)  1 (c) (0.48–2.09)  1 (c) (0.47–2.13) 
PROS 11  1.86 (1.31–2.64)  0.45 (0.22–0.95)  0.3 (0.15–0.59)  0.54 (0.39–0.74)  0.33 (0.2–0.55)  8.16 (2.0–33.22) 
PROS 12  1.40 (0.87–2.24)  0.34 (0.26–0.44)  0.35 (0.26–0.48)  0.21 (0.1–0.42)  0.26 (0.13–0.55)  1.22 (0.17–8.8) 
IND 11  Insuff  Insuff  Insuff  0.58 (0.21–1.65)  0.42 (0.22–0.8)  0.23 (0.01–6.1) 
IND 12  0.82 (0.58–1.18)  0.07 (0.02–0.3)  0.26 (0.2–0.34)  0.04 (0.02–0.06)  0.07 (0.05–0.1)  0.02 (0.01–0.03) 
IND 13  Insuff  Insuff  Insuff  65.12 (11.2–375.4)  0.99 (0.16–6.24)  6.12 (0.98–38.19) 
IND 14  0.79 (0.61–1.04)  0.16 (0.1–0.26)  0.03 (0.02–0.05)  Insuff  Insuff  Insuff 
IND 15  5.54 (3.53–8.69)  4.23 (2.91–6.16)  1.58 (0.19–12.85)  Insuff  Insuff  Insuff 
PROS 7  1 (c) (0.63–1.59)  1 (c) (0.78–1.28)  1 (c) (0.60–1.67)  1 (c) (0.53–1.88)  1 (c) (0.35–2.83)  1 (c) (0.45–2.23) 
PROS 8  36.59 (31.22–42.88)  19.12 (16.01–22.82)  142.7 (86.53–235.3)  29.24 (19.35–44.2)  78.43 (21.56–285.3)  654.8 (61.56–6,966.2) 
PROS 9  0.48 (0.31–0.74)  0.18 (0.13–0.25)  5.74 (1.11–29.65)  0.41 (0.25–0.67)  0.04 (0.02–0.09)  2,341.7(1,122.7–4,884.3) 
IND 1  0.44 (0.31–0.62)  0.03 (0.01–0.09)  1.19 (0.14–10.4)  0.005 (0.004–0.007)  0.001 (0–0.011)  0.004 (0.003–0.005) 
IND 2  5.27 (2.79–9.95)  3.09 (1.81–5.26)  ND  3.0 (2.16–4.16)  2.69 (0.47–15.37)  3.07 (0.57–16.45) 
IND 3  1.53 (1.22–1.92)  1.11 (0.62–1.99)  3.23 (1.61–6.5)  1.33 (0.81–2.16)  0.18 (0.004–8.7)  0.29 (0.01–6.63) 
PROS 1  Insuff  Insuff  Insuff  1 (c) (0.6–1.67)  1 (c) (0.1–10.14)  1 (c) (0.19–5.37) 
PROS 2  Insuff  Insuff  Insuff  8.46 (7.15–10.01)  23.5 (21.1–26.17)  0.45 (0.1–2.04) 
PROS 3  Insuff  Insuff  Insuff  0.12 (0.08–0.17)  1.96 (1.4–2.75)  0.16 (0.02–1.71) 
IND 4  Insuff  Insuff  Insuff  0.23 (0.1–0.54)  4.79 (3.62–6.34)  0.09 (0.06–0.13) 
IND 5  Insuff  Insuff  Insuff  ND  0.25 (0.03–2.24)  8.61 (2.59–28.69) 
IND 6  Insuff  Insuff  Insuff  20.02 (15.34–26.12)  9.47 (5.66–15.85)  4.37 (2.59–7.35) 
PROS 4  Insuff  Insuff  Insuff  1 (c) (0.67–1.49)  1 (c) (0.43–2.33)  1 (c) (0.19–5.32) 
PROS 5  Insuff  Insuff  Insuff  0.04 (0.02–0.08)  0.13 (0.09–0.17)  0.02 (0.02–0.02) 
PROS 6  Insuff  Insuff  Insuff  10.15 (4.1–25.11)  2.87 (1.31–6.26)  35.7 (15.2–83.8) 
IND 7  Insuff  Insuff  Insuff  13.64 (10.48–17.77)  0.99 (0.66–1.49)  6.26 (1.06–37.0) 
IND 8  Insuff  Insuff  Insuff  0.02 (0.02–0.03)  0.2 (0.14–0.29)  2.26 (1.31–3.89) 
IND 10  Insuff  Insuff  Insuff  0.04 (0.01–0.13)  0.33 (0.19–0.56)  0.01 (0.002–0.03) 
ND, not detected; c, calibrator control; Insuff, insufficient material. 
Patients who donated tissue for the research purpose of this study were chronologically numbered. For inter–individual variations, the mRNA transcript levels derived 
from the first patient number was arbitrarily taken as the calibrator (*) and set to 1 (for raw data, see Supplementary Information, Table 3S). Quantitative gene 
expression  was  carried  out  exactly  as  previously  described  [20,21],  with  minimum–maximum  expression  in  brackets.  Within  each  experiment,  reactions  were 
performed in triplicate and ‗no–template‘ controls were included. Averaged threshold cycle (CT) values for each reaction were normalized to -ACTIN values thus 
giving CT values. Alterations in gene expression were determined by comparison with the tissue value assigned as the calibrator, giving CT values. Finally, relative 
gene expression was calculated using the formula 2
–C
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Figure 2 shows the fluorescent immunolabelling of ER1 in benign prostate (2A, 2B) compared to 
that for its splice variant ER2 in UK benign prostate tissue (2C, 2D) and India benign prostate tissue 
(2E, 2F). As expected, a primarily nuclear–associated staining pattern is noted with ER1 (Figure 2A), 
and this is clearly shown when the fluorescein (antibody, i.e., green) and PI (nuclear, i.e., red) positive 
staining is superimposed on a phase contrast background (Figure 2B). In UK benign prostate tissue at 
low- (Figure 2C) and high-power (Figure 2D), clear nuclear-associated staining for the splice variant 
ER2 is observed. An equally high level of staining for ER2 in India benign prostate tissue, which is 
again  clearly  nuclear-associated,  was  observed  (Figure  2E,  2F).  Of  note,  in  the  small  number  of 
examples  examined  in  this  study  the  staining  for  ER2  appeared  to  be  more  intense  than  that 
associated with its full-length parent isoform. By imposing the fluorescent images on a phase contrast 
background (Figure 2B, 2E), one better visualises the spatial location of the protein (labelled green) 
with regards to the cell nuclei (labelled red) within the cells. Of course, the more important splice 
variant  to  investigate  would  be  ER5;  however,  to  the  best  of  our  knowledge  the  anti-ER5 
antibody is not currently available. 
Figure  2.  Representative  photomicrographs  in  human  prostate  of  staining  by 
immunofluorescence  over  the  range  500–540  nm  for  fluorescein  (green  antibody  label 
identifying the spatial location of the protein) and 624–707 nm for PI (red-stained nuclei). 
(A) ER in benign prostate tissue (PROS 12); (B) ER in benign prostate tissue (PROS 
12); (C) ER2 in benign prostate tissue (PROS 12); (D) ER2 in benign prostate tissue  
(PROS 12); (E) ER2 in benign prostate tissue (IND 8); and, (F) ER2 in benign prostate 
tissue (IND 8). 
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4. Discussion 
TA tissue is useful in that it has undergone the same environmental exposure and has the same 
genetic  source  as  a  cancer  arising  elsewhere  in  the  organ  but  it  lacks  the  chaotic  deregulation 
associated  with  malignancy.  It  is  therefore  valuable  in  assessing  the  status  of  the  tissue  prior  to 
carcinogenesis. We hypothesized that altered levels of ER splice variants, perhaps secondary to an 
underlying abnormal oestrogen balance, are present in these TA or high-risk tissues and, so potentially 
are involved in the malignant process. 
A large difference was found in the TA vs. normal prostate tissue in the level of ER5, with 
increased expression in all 9 of the RRP samples but only 2/9 of the benign TURP samples. The mean 
expression level in TA tissue was also over six-times higher than that in normal tissue (63.3 vs. 10.3), 
even  after  excluding  an  outlying  value.  ER5  is  a  truncated  receptor  and  lacks  most  of  the  
ligand-binding domain. It has constitutive activity, but only 5% of that of the full-length receptor and 
competitively inhibits the activity of ER by blocking DNA-binding sites. Although the role of ER 
has not been fully established in the prostate, it is frequently involved in growth promotion. The 
function of ER may be more complex in the prostate as it is unlikely that inhibiting this activity could 
promote CaP. It is possible that this raised level of ER5 is a contributory factor in preventing the TA 
tissue from undergoing malignant transformation. 
The explanation for this variation may not be a difference between TA and benign tissue but be due 
to a difference in the prostate tissue sampled; for example, different operations may favour tissue from 
slightly different zones. As ER5 is present at low levels, there are wide confidence intervals and this 
is a small sample; it is plausible that this difference is due to chance alone. In addition, the expression 
level of ER5, whilst increased, is still much lower than the expression level of ER, and may be too 
low to have any inhibitory effect. No other splice variant demonstrated any difference between the two 
groups. It is likely that ER3, ER2 and ER5 are not involved in any field effect in the early stages 
of  premalignant  transformation  in  prostate  tissue.  All  of  the  RRPs  were  performed  after  
biopsy-detected malignancy; however, two were found to contain benign tissue only. The tumours in 
the other seven were of Gleason grade 6 to 8, with the majority (5/9) being grade 6. Recent work has 
discovered that increased nuclear ER2 and ER5 in CaP are associated with a poor prognosis [19]. It 
is possible that higher-grade CaPs would have higher levels of ER2 and ER5 in adjacent tissue, 
although TA15, the only Gleason grade 4 + 4 TA tissue, did not have significantly increased levels of 
these splice variants. The ER splice variant expression levels for the UK and Indian prostate tissues 
were  comparable.  A  previous  study  has  found  similar  levels  of  gene  expression  of  phase  I/II 
metabolising  enzymes  between  a  UK  and  Indian  cohort,  but  clear  differences  were  found  on 
immunohistochemistry [21]. It would be interesting to discover whether this is also the case with the 
ER splice variants. 
In endometrial tissue none of the splice variants tested differed between TA tissue and normal 
benign tissue. Previous work has found that ER5 is raised and that the number of ER splice variants 
is increased in endometrial carcinoma [18,22]. This does not appear to be the case in TA tissue. If 
environmental or endogenous oestrogens do influence these processes, it is probably not via altered 
expression of these ER splice variants. This study has several limitations. The splice variants examined 
are present in small quantities and a highly sensitive technique, such as real-time RT PCR, is needed to Int. J. Environ. Res. Public Health 2010, 7                 
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quantify them. Confidence intervals are sometimes wide as the concentrations are occasionally at the 
limits of detection. We have used 60 cycles of RT-PCR as several of these splice variants are present at 
very low levels. This increases the risk of non-specific amplification and results were only counted if 
at least 2 of the 3 triplicate wells had similar results. Also, it was not possible to obtain a complete 
dataset for the prostate tissues due to limited cDNA. Cases and controls were not age or otherwise 
matched and, as this was planned as a pilot study, the number of tissues studied is not large. 
Despite these limitations, the study demonstrates that prostate tissue does normally contain ER 
splice variants at quantifiable levels; this has not previously been described at this tissue location. At 
physiological  concentrations,  it  is  known  that  oestrogens  can  induce  genetic  damage  [23],  so 
understanding  the  mechanisms  by  which  they  act  is  fundamentally  important  to  understanding 
carcinogenic processes in these target tissues [24-26]. This is the first study of ER splice variants in 
TA endometrial or prostate tissue and, the first of ER splice variants in normal tissue in populations at 
differing risk of developing CaP (i.e., UK vs. India). Whilst the results are predominantly negative, the 
findings related to ER5 in TA vs. benign prostate are potentially important and are worthy of more 
extensive study. 
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Appendix 
Table 1S. Benign vs. tumour-adjacent endometrial tissue, mean CT values (corresponding 
-ACTIN CT value). 
Code  ER  ER3  ER5  ER1  ER2  ER5 
N1  25.0 (19.2)  30.6 (19.2)  31.2 (19.2)  33.9 (18.7)  33.4 (18.7)  37.0 (18.7) 
N2  24.0 (19.2)  30.0 (19.2)  31.5 (19.2)  32.8 (18.5)  32.6 (18.5)  35.1 (18.5) 
N3  23.9 (19.4)  28.6 (19.4)  30.2 (19.4)  34.1 (18.8)  33.4 (18.8)  36.9 (18.8) 
TA1  24.7 (19.0)  30.4 (19.0)  31.9 (19.0)  31.1 (18.7)  32.9 (18.7)  33.9 (18.7) 
TA2  23.0 (17.7)  28.3 (17.7)  30.2 (17.7)  32.4 (17.7)  30.9 (17.7)  34.6 (17.7) 
TA3  24.4 (18.8)  30.1 (18.8)  31.2 (18.8)  34.0 (18.8)  32.7 (18.8)  37.1 (18.8) 
N4  26.4 (20.8)  31.1 (20.8)  31.5 (20.8)  30.1 (19.4)  33.5 (19.4)  39.4 (19.4) 
N5  29.0 (22.8)  32.5 (22.8)  33.7 (22.8)  20.7 (21.3)  34.5 (21.3)  40.3 (21.3) 
N6  26.0 (20.3)  30.8 (20.3)  30.8 (20.3)  34.1 (19.0)  33.7 (19.0)  37.7 (19.0) 
TA4  24.6 (20.2)  29.6 (20.2)  29.5 (20.2)  24.7 (18.3)  32.9 (18.3)  34.3 (18.3) 
TA5  24.3 (20.3)  29.5 (20.3)  29.8 (20.3)  35.3 (18.6)  33.4 (18.6)  37.0 (18.6) 
TA6  27.2 (22.7)  32.2 (22.7)  33.3 (22.7)  37.2 (21.4)  33.0 (21.4)  38.2 (21.4) 
N7  24.5 (19.0)  29.4 (19.0)  30.5 (19.0)  33.1 (18.9)  33.5 (18.9)  37.2 (18.9) 
N8  24.4 (19.1)  30.6 (19.1)  30.9 (19.1)  34.2 (18.8)  32.3 (18.8)  58.7 (18.8) 
N9  26.0 (19.9)  31.0 (19.9)  32.4 (19.9)  36.1 (20.0)  33.8 (20.0)  39.2 (20.0) 
TA7  24.0 (19.4)  29.7 (19.4)  31.3 (19.4)  32.1 (19.1)  32.5 (19.1)  36.6 (19.1) 
TA8  24.1 (18.5)  30.2 (18.5)  31.0 (18.5)  32.8 (18.5)  33.2 (18.5)  37.2 (18.5) 
TA9  23.2 (18.2)  28.6 (18.2)  30.0 (18.2)  32.6 (17.9)  31.8 (17.9)  38.9 (17.9) 
N, benign endometrial tissue code; TA, tumour-adjacent endometrial tissue code. 
This table presents the raw data required for the relative gene expression analysis shown in Table 2. The mean CT values 
of each gene investigated and the mean CT value of -ACTIN (in brackets), is given for each patient. Gene expression 
analysis is performed by comparing -ACTIN values with those of the gene of interest, relative to one ‗control‘ patient 
known as the calibrator (consequently assigned a gene expression value of 1) in order to determine relative inter-patient 
differences (see Table 2). Int. J. Environ. Res. Public Health 2010, 7                 
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Table 2S. Benign vs. tumour-adjacent prostate, mean CT values (corresponding -ACTIN 
CT value). 
Code  ER  ER3  ER5  ER1  ER2  ER5 
PROS 1  36.4 (23.9)  39.5 (23.9)  43.9 (23.9)  37.0 (24.4)  37.2 (24.4)  57.1 (24.4) 
PROS 2  34.4 (24.9)  36.6 (24.9)  44.4 (24.9)  34.8 (23.3)  35.0 (23.3)  53.2 (23.3) 
PROS 3  33.8 (20.7)  40.1 (20.7)  41.6 (20.7)  36.5 (20.3)  33.1 (20.3)  37.5 (20.3) 
TA 13  29.1 (19.7)  35.2 (19.7)  36.0 (19.7)  36.3 (19.5)  32.8 (19.5)  38.6 (19.5) 
TA 14  28.8 (19.0)  34.5 (19.0)  34.2 (19.0)  35.4 (18.3)  31.0 (18.3)  36.4 (18.3) 
TA 15  30.0 (21.0)  35.3 (21.0)  37.1 (21.0)  36.5 (21.2)  33.5 (21.2)  38.8 (21.2) 
PROS 4  41.3 (29.8)  43.0 (29.8)  56.1 (29.8)  Insuff  Insuff  Insuff 
PROS 5  39.0 (26.3)  48.2 (26.3)  53.2 (26.3)  Insuff  Insuff  Insuff 
PROS 6  37.7 (29.7)  39.3 (29.7)  50.3 (29.7)  Insuff  Insuff  Insuff 
TA 16  32.6 (29.4)  34.6 (29.4)  41.1 (29.4)  Insuff  Insuff  Insuff 
TA 17   37.3 (26.1)  40.0 (26.1)  43.8 (26.1)  Insuff  Insuff  Insuff 
TA 18   37.7 (26.6)  40.1 (26.6)  48.1 (26.6)  Insuff  Insuff  Insuff 
PROS 7  36.2 (25.8)  38.6 (25.8)  44.7 (25.8)  37.2 (25.7)  34.6 (25.7)  56.0 (25.7) 
PROS 8  31.6 (25.3)  32.9 (25.3)  39.1 (25.3)  31.2 (25.2)  31.7 (25.2)  42.1 (25.2) 
PROS 9  33.4 (21.9)  36.5 (21.9)  41.3 (21.9)  35.0 (21.2)  34.2 (21.2)  38.5 (21.2) 
TA14 19   33.0 (25.3)  35.5 (25.3)  40.4 (25.3)  36.0 (25.5)  23.3 (25.5)  48.2 (25.5) 
TA17 20  31.0 (21.7)  33.5 (21.7)  37.2 (21.7)  32.6 (21.5)  30.8 (21.5)  38.4 (21.5) 
TA21 21  32.1 (22.4)  34.9 (22.4)  38.2 (22.4)  Insuff  Insuff  Insuff 
TA8 22  Insuff  Insuff  Insuff  33.8 (20.1)  30.4 (20.1)  36.8 (20.1) 
PROS, benign prostate tissue code; TA, tumour-adjacent prostate tissue code; Insuff, insufficient material. 
This table presents the raw data required for the relative gene expression analysis shown in Table 3. The mean CT 
values of each gene investigated and the mean CT value of -ACTIN (in brackets), is given for each patient. Gene 
expression analysis is performed by comparing -ACTIN values with those of the gene of interest, relative to one 
‗control‘ patient known as the calibrator (consequently assigned a gene expression value of 1) in order to determine 
relative inter–patient differences (see Table 3). 
Table 3S. UK vs. India prostate, mean CT values (corresponding -ACTIN CT value). 
Code  ER  ER3  ER5  ER1  ER2  ER5 
PROS 10  39.2 (26.9)  40.2 (26.9)  41.5 (26.9)  39.8 (25.7)  35.8 (25.7)  45.8 (25.7) 
PROS 11  36.1 (24.7)  39.1 (24.7)  41.1 (24.7)  38.4 (23.4)  35.1 (23.4)  40.6 (23.4) 
PROS 12  33.9 (22.2)  37.0 (22.2)  38.2 (22.2)  37.5 (21.1)  33.2 (21.1)  41.0 (21.1) 
IND11  Insuff  Insuff  Insuff  37.8 (22.9)  34.3 (22.9)  45.2 (22.9) 
IND12  34.2 (21.8)  38.8 (21.8)  38.3 (21.8)  40.4 (21.6)  35.6 (21.6)  47.7 (21.6) 
IND13  Insuff  Insuff  Insuff  33.8 (25.7)  35.8 (25.7)  43.3 (25.7) 
IND14  34.6 (22.0)  37.9 (22.0)  41.6 (22.0)  Insuff  Insuff  Insuff 
IND15  36.8 (27.0)  38.2 (27.0)  40.9 (27.0)  Insuff  Insuff  Insuff 
PROS 7  35.7 (26.2)  37.3 (26.2)  45.4 (26.2)  36.2 (26.1)  48.7 (26.1)  51.4 (26.1) 
PROS 8  30.2 (25.9)  32.8 (25.9)  38.0 (25.9)  30.8 (25.6)  41.9 (25.6)  41.6 (25.6) 
PROS 9  32.9 (22.3)  35.9 (22.3)  39.0 (22.3)  34.0 (22.6)  50.0 (22.6)  36.7 (22.6) 
IND1  33.7 (23.1)  39.1 (23.1)  42.0 (23.1)  39.6 (21.8)  53.9 (21.8)  55.1 (21.8) 
IND2  35.7 (28.6)  38.1 (28.6)  42.4 (28.6)  35.4 (26.9)  48.1 (26.9)  50.6 (26.9) 
IND3  33.7 (24.9)  35.9 (24.9)  ND  33.0 (23.4)  48.5 (23.4)  50.5 (23.4) 
PROS 1  Insuff  Insuff  Insuff  36.6 (23.8)  37.8 (23.8)  41.3 (23.8) Int. J. Environ. Res. Public Health 2010, 7                 
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Table 3S. Cont. 
Code  ER  ER3  ER5  ER1  ER2  ER5 
PROS 2  Insuff  Insuff  Insuff  34.4 (24.6)  34.1 (24.6)  43.2 (24.6) 
PROS 3  Insuff  Insuff  Insuff  36.5 (20.5)  33.6 (20.5)  40.6 (20.5) 
IND4  Insuff  Insuff  Insuff  40.3 (23.4)  37.1 (23.4)  46.2 (23.4) 
IND5  Insuff  Insuff  Insuff  ND  46.0 (30.0)  44.4 (30.0) 
IND6  Insuff  Insuff  Insuff  32.1 (23.6)  34.4 (23.6)  38.9 (23.6) 
PROS 4  Insuff  Insuff  Insuff  38.1 (27.3)  37.3 (27.3)  44.4 (27.3) 
PROS 5  Insuff  Insuff  Insuff  38.7 (23.2)  36.2 (23.2)  45.9 (23.2) 
PROS 6  Insuff  Insuff  Insuff  35.3 (27.8)  36.4 (27.8)  39.8 (27.8) 
IND7  Insuff  Insuff  Insuff  32.4 (25.3)  35.4 (25.3)  39.8 (25.3) 
IND8  Insuff  Insuff  Insuff  37.2 (21.0)  33.4 (21.0)  37.0 (21.0) 
IND10  Insuff  Insuff  Insuff  38.8 (23.4)  35.0 (23.4)  47.6 (23.4) 
ND, not detected; Insuff, insufficient material. 
PROS, Benign UK-resident prostate tissue code; IND, Benign India-resident prostate tissue code 
This table presents the raw data required for the relative gene expression analysis shown in Table 4. The mean CT 
values of each gene investigated and the mean CT value of -ACTIN (in brackets), is given for each patient. Gene 
expression analysis is performed by comparing -ACTIN values with those of the gene of interest, relative to one 
‗control‘ patient known as the calibrator (consequently assigned a gene expression value of 1) in order to determine 
relative inter–patient differences (see Table 4). 
Table 4S. Prostate samples demographic details. 
Code  Age (y)  PSA (ng/mL)  Gleason grade 
PROS 1  71  3.75  NA 
PROS 2  81  4.99  NA 
PROS 3  72  NK  NA 
PROS 4  72  4.96  NA 
PROS 5  73  2.49  NA 
PROS 6  74  6.25  NA 
PROS 7  81  5  NA 
PROS 8  62  5.7  NA 
PROS 9 (open)  82  34  NA 
PROS 10  79  3.75  NA 
PROS 11  71  4.19  NA 
PROS 12 (open)  73  5  NA 
TA 13  60  11.5  3 + 3 
TA 14  61  8.2  3 + 3 
TA 15  64  8.7  4 + 4 
TA 16  65  6.5  3 + 3 
TA 17  56  2.7  benign 
TA 18  67  NK  benign 
TA 19  NK  NK  NK 
TA 20  66  9  3 + 3 
TA 21  57  5.3  3 + 3 
TA 22  63  5.8  3 + 4 
IND 1  58  1.2  NA 
IND 2  60  2.4  NA Int. J. Environ. Res. Public Health 2010, 7                 
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Table 4S. Cont. 
Code  Age (y)  PSA (ng/mL)  Gleason grade 
IND 3  63  0.3  NA 
IND 4  76  3.2  NA 
IND 5  75  0.3  NA 
IND 6  65  0.2  NA 
IND 7  79  2.5  NA 
IND 8  74  0.3  NA 
IND 9  65  0.6  NA 
IND 10  NK  NK  NA 
IND 11  62  3.3  NA 
IND 12  47  2.4  NA 
IND 13  64  2.4  NA 
IND 14  60  0.3  NA 
IND 15  74  1.4  NA 
NK, not known; NA, not applicable; open, open prostatectomy. 
PROS, Benign UK-resident prostate tissue code; TA, tumour-adjacent prostate tissue code; 
IND, Benign India-resident prostate tissue code. 
Table 5S. Endometrial samples demographic details. 
Code  Age (y)  Histology  Stage 
N1  39  proliferative   NA 
N2  46  early proliferative  NA 
N3  42  proliferative  NA 
N4  39  proliferative  NA 
N5  46  proliferative  NA 
N6  51  proliferative  NA 
N7  42  proliferative  NA 
N8  43  proliferative to early secretory with simple hyperplasia  NA 
N9  43  proliferative  NA 
TA1  58  G2 endometrioid  3a 
TA2  74  G2 endometrioid  1c 
TA3  67  G2 endometrioid  1b 
TA4  84  G2 endometrioid  1a 
TA5  57  G2 endometrioid  1a 
TA6  77  G2 endometrioid  1c 
TA7  70  G2 endometrioid  1b 
TA8  62  G2 endometrioid  1b 
TA9  62  G2 endometrioid  2a 
N, benign endometrial tissue code;  
TA, tumour-adjacent endometrial tissue code;  
NA, not applicable. 
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